Immunogenicity in protein and peptide based-therapeutics: An overview

L. Fernández, R. H. Bustos*, C. Zapata, J. García, E. Jaúregui, G. M. Ashraf

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Citations (Scopus)

Abstract

Currently it is well known that all biological drugs, including those with a fully human structure, are capable of inducing a host immune response known as immunogenicity [1]. The presence of ADAs can condition the drug´s level and action, thus modifying the therapeutic effect and even the safety profile by its mechanism of action-neutralizing or non-neutralizing-and / or an increase in its clearance. Immunogenicity is a dynamic factor to be taken into account in biological therapy, especially in long-term treatments, and as a relevant aspect in the assessment of secondary response loss [2]. With the above, not only the knowledge but also the management of the immunogenicity of the different biological treatments, represent a useful instrument for optimization of the strategies of use for each drug, and in the design of predictive models of response, which finally permits a significant improvement in the efficacy and safety profile, aiming to a personalization of the therapies, especially in patients with autoimmune diseases, genetic disorders and cancer [3]. This review summarizes the events of immunogenicity that produce the biological drug, the factor that influence to immunogenicity and the assessment of immunogenicity.

Original languageEnglish
Pages (from-to)958-971
Number of pages14
JournalCurrent Protein and Peptide Science
Volume19
Issue number10
DOIs
Publication statusPublished - 2018
Externally publishedYes

Keywords

  • ADAs
  • Anti-drugs antibodies
  • Biological drugs
  • Biosensor
  • Immunogenicity
  • Peptide

Fingerprint

Dive into the research topics of 'Immunogenicity in protein and peptide based-therapeutics: An overview'. Together they form a unique fingerprint.

Cite this